Bluefin Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Bluefin Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-330,000	Closed	-$4K	–	489
2018 Q4	$4K	Hold	330,000	–	–	﹤0.01%	392
2018 Q3	$10K	Hold	330,000	–	–	﹤0.01%	477
2018 Q2	$9K	Sell	330,000 -515,000	-61%	-$10.5M	﹤0.01%	391
2018 Q1	$40K	Buy	845,000 +215,000	+34%	+$4.2M	﹤0.01%	348
2017 Q4	$27K	Buy	+630,000	New	+$9.48M	﹤0.01%	410
2016 Q1	–	Sell	-64,400	Closed	-$428K	–	713
2015 Q4	$428K	Buy	+64,400	New	+$3.98M	0.03%	323
2015 Q3	–	Sell	-151,800	Closed	-$200K	–	596
2015 Q2	$200K	Buy	+151,800	New	+$9.36M	0.01%	436
2014 Q4	–	Sell	-15,000	Closed	-$33K	–	894
2014 Q3	$33K	Buy	+15,000	New	+$795K	﹤0.01%	783

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Bluefin Capital Management's TEVA Position: Q1 2022 in Review

Bluefin Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2022, closing a stake of 15,237 shares — an estimated $122K sold.

Bluefin Capital Management first reported a position in TEVA in Q3 2014 and held it in 10 quarters. The position peaked at $4.57M in Q2 2015. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2022.

Bluefin Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Bluefin Capital Management sold 15,237 Teva Pharmaceuticals shares in Q1 2022, an estimated $122K.
Bluefin Capital Management first reported a position in Teva Pharmaceuticals in Q3 2014 and held it in 10 quarters.
Bluefin Capital Management's Teva Pharmaceuticals position peaked at $4.57M in Q2 2015.
438 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2022.

Based on Bluefin Capital Management's 13F filing for Q1 2022, filed 16 May 2022.